Hypomyelinating Leukodystrophy 7 (HLD7) — Disease Characteristics Research Report

Executive summary

Hypomyelinating leukodystrophy 7 (HLD7) is an autosomal recessive, POLR3A-associated hypomyelinating leukodystrophy within the POLR3-related leukodystrophy/“4H leukodystrophy” spectrum, characterized by central nervous system hypomyelination and frequent extra-neurologic dental and endocrine involvement. Key diagnostic clues are a characteristic brain MRI pattern plus confirmatory biallelic POLR3A variants. Recent (2023–2024) work emphasizes mechanistic links between POLR3A dysfunction, abnormal RNA polymerase III transcript output, and impaired myelin biology, and calls for precision-medicine approaches (single-cell omics, cell-based drug screening) to enable future targeted therapies. (torii2023molecularpathogenicmechanisms pages 1-2, wolf2014clinicalspectrumof pages 1-2, macintosh2023biallelicpathogenicvariants pages 1-2, ruan2024clinicalphenotypeand pages 1-2)

Table: This table condenses the key disease-level facts for Hypomyelinating Leukodystrophy 7, including identifiers, gene, phenotype, MRI, representative variants, and recent mechanistic/model advances. It is useful as a compact evidence-backed reference for building a disease knowledge base entry.

1. Disease information

1.1 Definition/overview

HLD7 is described as an autosomal recessive neurodegenerative disorder with childhood-onset progressive motor decline and CNS hypomyelination, historically grouped under “4H leukodystrophy” (hypomyelination, hypodontia, hypogonadotropic hypogonadism) and broader “POLR3-related leukodystrophy / POLR3-HLD” terminology. (wu2019novelmutationsof pages 1-4, wu2019novelmutationsof pages 4-6, macintosh2023biallelicpathogenicvariants pages 1-2)

Direct abstract-anchored definition examples: - “Hypomyelinating leukodystrophy 7 (HLD7) is an autosomal recessive neurodegenerative disorder” (case report text) (wu2019novelmutationsof pages 4-6). - 4H leukodystrophy is “typically characterized by the triad of hypomyelination, hypodontia, and hypogonadotropic hypogonadism.” (wolf2014clinicalspectrumof pages 1-2)

1.2 Key identifiers

• OMIM/MIM disease ID: 607694 (HLD7) (lynch2022clinicalandgenetic pages 42-46, torii2023molecularpathogenicmechanisms pages 1-2, cayami20184hleukodystrophylessons pages 1-2, wolf2014clinicalspectrumof pages 1-2)
• Causal gene: POLR3A (see Genetics section) (lynch2022clinicalandgenetic pages 42-46, torii2023molecularpathogenicmechanisms pages 1-2)
• MONDO / Orphanet / ICD / MeSH: Not available from the retrieved primary sources in this run; should be pulled from OMIM/Orphanet/MONDO directly during KB curation (not reliably inferable from the present evidence set).

1.3 Synonyms and alternative names

Commonly used overlapping terms in the literature: - Hypomyelinating leukodystrophy 7 (HLD7) (torii2023molecularpathogenicmechanisms pages 1-2) - 4H leukodystrophy (wolf2014clinicalspectrumof pages 1-2) - POLR3-related leukodystrophy / POLR3-HLD (macintosh2023biallelicpathogenicvariants pages 1-2) - In adult leukoencephalopathy differential-diagnosis tables, HLD7 is also labeled by its classic triad: “Hypomyelination, hypogonadotropic hypogonadism and hypodontia.” (lynch2022clinicalandgenetic pages 42-46)

1.4 Evidence source types

Evidence summarized here is primarily from: - Aggregated disease-level resources (reviews and cross-sectional case series) (torii2023molecularpathogenicmechanisms pages 1-2, wolf2014clinicalspectrumof pages 1-2) - Individual/family case reports with functional follow-up (ruan2024clinicalphenotypeand pages 1-2, wu2019novelmutationsof pages 4-6) - Diagnostic cohort sequencing studies (WES-based molecular diagnosis) (yan2021geneticanalysisof pages 4-6)

2. Etiology

2.1 Disease causal factors

Genetic (primary): HLD7 is caused by biallelic pathogenic variants in POLR3A, encoding the largest subunit of RNA polymerase III (Pol III), which transcribes many small non-coding RNAs including tRNAs and 5S rRNA. (yan2021geneticanalysisof pages 4-6, torii2023molecularpathogenicmechanisms pages 1-2, ruan2024clinicalphenotypeand pages 1-2)

Disease context: HLD7 sits within the broader POLR3-related leukodystrophy group arising from biallelic variants in Pol III subunit genes, including POLR3A and other subunits (e.g., POLR3B, POLR1C, POLR3K; and newer causes such as POLR3D). (ruan2024clinicalphenotypeand pages 1-2, macintosh2023biallelicpathogenicvariants pages 1-2)

2.2 Risk factors

• Family history / consanguinity increases likelihood because inheritance is autosomal recessive; an HLD7 family report explicitly involved consanguineous parents who were heterozygous carriers while affected siblings were homozygous. (ruan2024clinicalphenotypeand pages 1-2)

No robust, disease-specific environmental risk factors were identified in the retrieved evidence set.

2.3 Protective factors

No genetic or environmental protective factors were identified in the retrieved evidence set.

2.4 Gene–environment interactions

No HLD7-specific gene–environment interactions were identified in the retrieved evidence set.

3. Phenotypes (clinical features)

3.1 Neurologic phenotypes (symptoms/signs)

Typical neurologic manifestations described across case series/case reports include: - Progressive motor impairment with spasticity, ataxia, tremor, dystonia, dysarthria (wu2019novelmutationsof pages 1-4, wu2019novelmutationsof pages 4-6, ruan2024clinicalphenotypeand pages 1-2) - Cognitive impairment/regression (wu2019novelmutationsof pages 4-6, ruan2024clinicalphenotypeand pages 1-2)

Direct quote example (case report): progressive motor decline manifests as “spasticity, ataxia, tremor, and cerebellar symptoms, as well as mild cognitive regression.” (wu2019novelmutationsof pages 4-6)

Age of onset / course: Onset can vary from childhood to adulthood; unusually late onset has been documented in siblings with first symptoms at ages 19 and 41, highlighting phenotypic heterogeneity. (campopiano2020anovelpolr3a pages 1-2)

3.2 Extra-neurologic phenotypes

Common extra-neurologic features in the POLR3-related/4H spectrum include: - Dental anomalies (hypodontia/hypodontia spectrum; dentin dysplasia) (wolf2014clinicalspectrumof pages 1-2, ruan2024clinicalphenotypeand pages 1-2) - Hypogonadotropic hypogonadism (wolf2014clinicalspectrumof pages 1-2, ruan2024clinicalphenotypeand pages 1-2)

Example from a 2024 family study: proband had “progressive cognitive decline, dentin dysplasia, and hypogonadotropic hypogonadism.” (ruan2024clinicalphenotypeand pages 1-2)

3.3 Imaging phenotypes (MRI)

A key disease concept is that HLD7 is defined by hypomyelination on MRI with a pattern that helps distinguish POLR3-related leukodystrophy from other hypomyelinating disorders: - Pattern description (cross-sectional series): “hypomyelination with relative T2 hypointensity of the ventrolateral thalamus, optic radiation, globus pallidus, and dentate nucleus, cerebellar atrophy, and thinning of the corpus callosum.” (wolf2014clinicalspectrumof pages 1-2) - 3T imaging series: “a relatively hypointense signal of the optic radiation, the ventrolateral thalamus, part of the posterior limb of the internal capsule(PLIC) and the dentate nucleus.” (cayami20184hleukodystrophylessons pages 1-2)

Example from a 2024 family study: MRI showed “bilateral periventricular white matter atrophy, brain atrophy, and corpus callosum atrophy and thinning.” (ruan2024clinicalphenotypeand pages 1-2)

3.4 Suggested HPO terms (non-exhaustive)

(Concept-to-HPO mapping suggestions; frequencies not consistently available in the evidence set) - Hypomyelination (HP:0003429) - Leukodystrophy (HP:0002415) - Ataxia (HP:0001251) - Spasticity (HP:0001257) - Tremor (HP:0001337) - Dystonia (HP:0001332) - Dysarthria (HP:0001260) - Cognitive impairment / intellectual disability (HP:0100543 / HP:0001249) - Hypodontia (HP:0000668) - Hypogonadotropic hypogonadism (HP:0000041)

3.5 Quality of life impact

Formal QoL instruments were not identified in the retrieved evidence set; however, severe motor disability and cognitive regression (e.g., tetraparesis in late-onset siblings) implies major impact on activities of daily living. (campopiano2020anovelpolr3a pages 1-2)

4. Genetic / molecular information

4.1 Causal gene(s)

• POLR3A (RNA polymerase III subunit A; Pol III catalytic core component) is consistently implicated as the causal gene for HLD7 (MIM 607694). (yan2021geneticanalysisof pages 4-6, lynch2022clinicalandgenetic pages 42-46, torii2023molecularpathogenicmechanisms pages 1-2)

4.2 Pathogenic variants (examples; not exhaustive)

Variant classes observed: missense, splice-region/splice-altering, frameshift, and in-frame insertion variants are reported. (ruan2024clinicalphenotypeand pages 1-2, yan2021geneticanalysisof pages 4-6, wu2019novelmutationsof pages 4-6, musumeci2022identificationofa pages 3-5)

Representative examples with nomenclature: - POLR3A NM_007055.4: c.2300G>T (p.Cys767Phe), homozygous in affected siblings from a consanguineous family. (ruan2024clinicalphenotypeand pages 1-2) - POLR3A c.1771-6C>G (splice-region) and c.2611del (p.M871Cfs*8) as compound heterozygous variants. (wu2019novelmutationsof pages 4-6) - Trio-WES cohort: c.661_662insCCT (p.(P220_L221insS)) and c.1770+5G>C, with splicing disruption leading to p.(P591Vfs*28). (yan2021geneticanalysisof pages 4-6) - Cohort report of severe POLR3-related leukodystrophy: novel missense c.328A>G (p.Lys110Glu) described as “Likely Pathogenic” by the authors. (musumeci2022identificationofa pages 3-5)

Variant prevalence statistic (disease-spectrum level): in a 105-patient mutation-proven series, a recurrent POLR3B allele (not POLR3A) was highlighted (c.1568T>A) and associated with milder phenotypes when homozygous, reinforcing gene- and allele-dependent severity differences across POLR3-related leukodystrophy. (wolf2014clinicalspectrumof pages 1-2)

4.3 Functional consequences (human functional studies)

A 2024 family study provided direct functional evidence for a POLR3A missense allele: - Wild-type POLR3A overexpression enhanced Pol III transcription (5S rRNA and tRNA Leu-CAA), whereas the p.Cys767Phe mutant showed impaired Pol III transcription, with reduced Pol III transcript outputs and decreased MBP expression. (ruan2024clinicalphenotypeand pages 1-2)

4.4 Modifier genes, epigenetics, chromosomal abnormalities

No HLD7-specific modifier genes, epigenetic mechanisms, or chromosomal abnormalities were identified in the retrieved evidence set.

5. Environmental information

No disease-specific environmental/lifestyle/infectious contributors were identified in the retrieved evidence set. HLD7 is primarily genetic. (wu2019novelmutationsof pages 4-6)

6. Mechanism / pathophysiology

6.1 Current understanding (causal chain)

1) Biallelic POLR3A variants impair Pol III function (core transcriptional machinery for many small non-coding RNAs). (ruan2024clinicalphenotypeand pages 1-2) 2) This leads to abnormal Pol III transcript output (e.g., altered 5S rRNA, tRNAs; in the 2024 family study, decreased POLR3A/BC200/tRNA Leu-CAA signals and decreased MBP/18S rRNA readouts were reported). (ruan2024clinicalphenotypeand pages 1-2) 3) Downstream, impaired RNA homeostasis and translation-related processes are hypothesized to perturb oligodendrocyte and myelin biology, yielding hypomyelination and progressive neurologic dysfunction, consistent with the clinical and MRI phenotype. (torii2023molecularpathogenicmechanisms pages 1-2, ruan2024clinicalphenotypeand pages 1-2)

6.2 Suggested ontology terms

GO Biological Process (suggestions): - tRNA transcription by RNA polymerase III (GO:0006383) - 5S rRNA transcription (GO:0009303) - Oligodendrocyte differentiation (GO:0048709) - Central nervous system myelination (GO:0022010)

Cell Ontology (CL) (suggestions): - Oligodendrocyte (CL:0000128) - Oligodendrocyte precursor cell (OPC) (CL:0002453)

7. Anatomical structures affected

7.1 Organ/system level

• Primary system affected: central nervous system (brain white matter), consistent with leukodystrophy/hypomyelination definitions and MRI findings. (torii2023molecularpathogenicmechanisms pages 1-2, wolf2014clinicalspectrumof pages 1-2)

7.2 Tissue/cell level

• White matter / myelin and the oligodendrocyte lineage are central to disease expression as inferred from the hypomyelination phenotype and mechanistic framing in POLR3-HLD literature. (torii2023molecularpathogenicmechanisms pages 1-2, ruan2024clinicalphenotypeand pages 1-2)

7.3 UBERON suggestions

• Brain white matter (UBERON:0006102)
• Corpus callosum (UBERON:0002335)
• Cerebellum (UBERON:0002037)

8. Temporal development

• Onset: variable; can be childhood-onset and progressive, but late onset has been documented (symptom onset at 19 and 41 years in siblings). (wu2019novelmutationsof pages 4-6, campopiano2020anovelpolr3a pages 1-2)
• Progression: typically progressive motor and cognitive decline; examples include evolution to tetraparesis and severe cognitive regression in a late-onset sibling. (campopiano2020anovelpolr3a pages 1-2)

9. Inheritance and population

• Inheritance: autosomal recessive / biallelic. (lynch2022clinicalandgenetic pages 42-46, wu2019novelmutationsof pages 4-6, macintosh2023biallelicpathogenicvariants pages 1-2)
• Epidemiology: disease prevalence/incidence estimates were not available in the retrieved evidence set.
• Sex ratio: not established in the retrieved evidence set.
• Founder effects: not established for HLD7 specifically in the retrieved evidence set (though founder/recurrent variants are discussed in the broader POLR3-related spectrum). (wolf2014clinicalspectrumof pages 1-2)

10. Diagnostics

10.1 Clinical/imaging diagnosis

MRI is central for recognition of hypomyelinating leukodystrophies and for pattern recognition supporting POLR3-related leukodystrophy: - Classic MRI pattern described in a 105-case series: “hypomyelination with relative T2 hypointensity of the ventrolateral thalamus, optic radiation, globus pallidus, and dentate nucleus, cerebellar atrophy, and thinning of the corpus callosum.” (wolf2014clinicalspectrumof pages 1-2)

10.2 Genetic testing (real-world implementation)

• Trio sequencing approaches are used in practice; one HLD7 report used trio medical exome sequencing to identify compound heterozygous POLR3A variants with co-segregation. (wu2019novelmutationsof pages 4-6)
• In a trio-WES cohort study of hypomyelinating leukodystrophy, POLR3A variants were among the detected causes and splice disruption was functionally supported by minigene assay. (yan2021geneticanalysisof pages 4-6)

10.3 Differential diagnosis

The retrieved evidence does not provide a structured differential list, but HLD7 should be considered among other hypomyelinating leukodystrophies; broad diagnostic approaches emphasize integrating MRI pattern recognition with molecular testing. (torii2023molecularpathogenicmechanisms pages 1-2, wolf2014clinicalspectrumof pages 1-2)

11. Outcome / prognosis

Natural history, survival, and validated prognostic factors were not quantified in the retrieved evidence set. Available case reports demonstrate substantial variability, ranging from progressive childhood neurodegeneration to later-onset milder courses, and severe disability can develop. (campopiano2020anovelpolr3a pages 1-2)

12. Treatment

12.1 Current standard of care

No disease-modifying therapy for HLD7 was identified in the retrieved evidence set. Management is described as multidisciplinary and symptomatic, consistent with general leukodystrophy care practices. (ruan2024clinicalphenotypeand pages 12-13)

12.2 Emerging/experimental approaches (research stage)

A 2024 precision-medicine review describes efforts to build platforms for early detection and therapeutic development in leukodystrophies (including POLR3-related leukodystrophy), emphasizing single-cell omics and drug screening rather than established clinical interventions. (coulombe2024towardsatreatment pages 2-4)

12.3 Clinical trials

No interventional clinical trials specific to HLD7/POLR3A were identified in the clinical trial search results available in this run (trials retrieved were for other leukodystrophies such as metachromatic leukodystrophy). Therefore, HLD7-specific trial status cannot be asserted from the current evidence set.

12.4 MAXO term suggestions (supportive)

• Genetic counseling (MAXO:0000074)
• Physical therapy / rehabilitation therapy (MAXO:0000012)
• Speech therapy (MAXO:0000126)
• Symptomatic management (MAXO:0000159)

13. Prevention

Because HLD7 is autosomal recessive, prevention is primarily via carrier testing, reproductive counseling, and prenatal/preimplantation genetic testing where appropriate; disease-specific guidelines were not retrieved here, but the inheritance pattern is well established. (lynch2022clinicalandgenetic pages 42-46, wu2019novelmutationsof pages 4-6)

14. Other species / natural disease

No naturally occurring non-human disease analogs were identified in the retrieved evidence set.

15. Model organisms

The retrieved evidence set did not include detailed animal-model phenotype excerpts for HLD7-specific alleles; however, the literature acknowledges model limitations for some POLR3A alleles and the need for appropriate allele/model selection when studying POLR3-related disease biology. (ruan2024clinicalphenotypeand pages 13-13)

Recent developments (2023–2024) — highlighted points

1) Updated mechanistic synthesis (2023): A 2023 review explicitly lists HLD7 as OMIM 607694 with causal gene POLR3A, situating it within the expanding genetic landscape of hypomyelinating leukodystrophies enabled by next-generation sequencing. (torii2023molecularpathogenicmechanisms pages 1-2) 2) Human functional validation (2024): A 2024 family study reports POLR3A c.2300G>T (p.Cys767Phe) and provides functional evidence of impaired Pol III transcription with downstream reduction in myelin-related expression readouts (e.g., MBP). (ruan2024clinicalphenotypeand pages 1-2) 3) Precision-medicine strategy proposals (2024): A 2024 review proposes single-cell omics and systematic drug screening platforms to stratify leukodystrophy patients and develop rational therapies, explicitly including POLR3-related leukodystrophy within scope. (coulombe2024towardsatreatment pages 2-4)

Key statistics and data points (from retrieved primary literature)

• 105 mutation-proven cases of 4H leukodystrophy caused by POLR3A/POLR3B were analyzed in a multinational cross-sectional study, with noted gene-dependent severity (“milder in patients with POLR3B than in patients with POLR3A mutations”). (wolf2014clinicalspectrumof pages 1-2)
• A 3T MRI series reported 12 patients with mutations distributed across POLR3 genes (POLR3A n=8; POLR3B n=3; POLR1C n=1) and described additional imaging signs at higher field strength. (cayami20184hleukodystrophylessons pages 1-2)
• A case-report literature summary stated: “There are 62 pathogenic variants associated with POLR3-related leukodystrophy,” and that “14 different mutations in the POLR3A gene have been reported” (note: case-report level compilation; may not reflect current database totals). (wu2019novelmutationsof pages 4-6)

Authoritative interpretation / expert perspective (evidence-backed)

The contemporary view is that HLD7 is best understood within the POLR3-related leukodystrophy spectrum, where diagnostic confidence comes from the combination of a recognizable MRI pattern and biallelic pathogenic variants, while clinical severity is heterogeneous and not fully explained by genotype alone—motivating current 2023–2024 emphasis on mechanistic studies (Pol III transcript dysregulation) and precision-medicine platforms to identify vulnerable cell types and candidate interventions. (torii2023molecularpathogenicmechanisms pages 1-2, wolf2014clinicalspectrumof pages 1-2, coulombe2024towardsatreatment pages 2-4, ruan2024clinicalphenotypeand pages 1-2)

Source URLs (most central)

• Wolf et al., Neurology (2014-11), “Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations.” https://doi.org/10.1212/WNL.0000000000001002 (wolf2014clinicalspectrumof pages 1-2)
• Cayami et al., Neuropediatrics (published online 2017-11-27; issue 2018-11), “4H Leukodystrophy: Lessons from 3T Imaging.” https://doi.org/10.1055/s-0037-1608780 (cayami20184hleukodystrophylessons pages 1-2)
• Ruan et al., Scientific Reports (2024-04), “Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by POLR3A mutation.” https://doi.org/10.1038/s41598-024-58452-6 (ruan2024clinicalphenotypeand pages 1-2)
• Torii & Yamauchi, Neurology International (2023-09), “Molecular Pathogenic Mechanisms of Hypomyelinating Leukodystrophies (HLDs).” https://doi.org/10.3390/neurolint15030072 (torii2023molecularpathogenicmechanisms pages 1-2)
• Coulombe et al., Biomolecules (2024-07), “Towards a Treatment for Leukodystrophy Using Cell-Based Interception and Precision Medicine.” https://doi.org/10.3390/biom14070857 (coulombe2024towardsatreatment pages 2-4)

References

1. (torii2023molecularpathogenicmechanisms pages 1-2): Tomohiro Torii and Junji Yamauchi. Molecular pathogenic mechanisms of hypomyelinating leukodystrophies (hlds). Neurology International, 15:1155-1173, Sep 2023. URL: https://doi.org/10.3390/neurolint15030072, doi:10.3390/neurolint15030072. This article has 18 citations.

2. (wolf2014clinicalspectrumof pages 1-2): Nicole I. Wolf, Adeline Vanderver, Rosalina M.L. van Spaendonk, Raphael Schiffmann, Bernard Brais, Marianna Bugiani, Erik Sistermans, Coriene Catsman-Berrevoets, Johan M. Kros, Pedro Soares Pinto, Daniela Pohl, Sandya Tirupathi, Petter Strømme, Ton de Grauw, Sébastien Fribourg, Michelle Demos, Amy Pizzino, Sakkubai Naidu, Kether Guerrero, Marjo S. van der Knaap, and Geneviève Bernard. Clinical spectrum of 4h leukodystrophy caused by polr3a and polr3b mutations. Neurology, 83:1898-1905, Nov 2014. URL: https://doi.org/10.1212/wnl.0000000000001002, doi:10.1212/wnl.0000000000001002. This article has 245 citations and is from a highest quality peer-reviewed journal.

3. (macintosh2023biallelicpathogenicvariants pages 1-2): Julia Macintosh, Stefanie Perrier, Maxime Pinard, Luan T. Tran, Kether Guerrero, Chitra Prasad, Asuri N. Prasad, Tomi Pastinen, Isabelle Thiffault, Benoit Coulombe, and Geneviève Bernard. Biallelic pathogenic variants in polr3d alter trna transcription and cause a hypomyelinating leukodystrophy: a case report. Frontiers in Neurology, Oct 2023. URL: https://doi.org/10.3389/fneur.2023.1254140, doi:10.3389/fneur.2023.1254140. This article has 17 citations and is from a peer-reviewed journal.

4. (ruan2024clinicalphenotypeand pages 1-2): Dan-dan Ruan, Xing-Lin Ruan, Ruolong Wang, Xin-fu Lin, Yan-ping Zhang, Bin Lin, Shi-jie Li, Min Wu, Qian Chen, Jian-Hui Zhang, Qiong Cheng, Yi-wu Zhang, Fan Lin, Jie-wei Luo, Zheng Zheng, and Yun-fei Li. Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by polr3a mutation. Scientific Reports, Apr 2024. URL: https://doi.org/10.1038/s41598-024-58452-6, doi:10.1038/s41598-024-58452-6. This article has 5 citations and is from a peer-reviewed journal.

5. (lynch2022clinicalandgenetic pages 42-46): David S. Lynch, Anderson Rodrigues Brandão de Paiva, Wei Zhang, E. Bugiardini, F. Freua, L. Tavares Lucato, Lúcia I Macedo-Souza, R. Lakshmanan, J. Kinsella, Á. Merwick, A. Rossor, N. Bajaj, B. Herron, P. Mcmonagle, P. Morrison, D. Hughes, A. Pittman, M. Laurá, M. Reilly, J. Warren, C. Mummery, J. Schott, M. Adams, Nick C Fox, E. Murphy, I. Davagnanam, F. Kok, J. Chataway, and H. Houlden. Clinical and genetic characterization of leukoencephalopathies in adults. Brain, 140:1204-1211, Mar 2022. URL: https://doi.org/10.1093/brain/awx045, doi:10.1093/brain/awx045. This article has 85 citations and is from a highest quality peer-reviewed journal.

6. (cayami20184hleukodystrophylessons pages 1-2): Ferdy Cayami, Marianna Bugiani, Petra Pouwels, Geneviève Bernard, Marjo van der Knaap, and Nicole Wolf. 4h leukodystrophy: lessons from 3t imaging. Neuropediatrics, 49:112-117, Nov 2018. URL: https://doi.org/10.1055/s-0037-1608780, doi:10.1055/s-0037-1608780. This article has 21 citations and is from a peer-reviewed journal.

7. (yan2021geneticanalysisof pages 4-6): Huifang Yan, Haoran Ji, Thomas Kubisiak, Ye Wu, Jiangxi Xiao, Qiang Gu, Yanling Yang, Han Xie, Taoyun Ji, Kai Gao, Dongxiao Li, Hui Xiong, Zhen Shi, Ming Li, Yuehua Zhang, Ruoyu Duan, Xinhua Bao, Yuwu Jiang, Margit Burmeister, and Jingmin Wang. Genetic analysis of 20 patients with hypomyelinating leukodystrophy by trio-based whole-exome sequencing. Journal of Human Genetics, 66:761-768, Feb 2021. URL: https://doi.org/10.1038/s10038-020-00896-5, doi:10.1038/s10038-020-00896-5. This article has 54 citations and is from a peer-reviewed journal.

8. (wu2019novelmutationsof pages 1-4): Shuiyan Wu, Zhenjiang Bai, Xingqiang Dong, Daoping Yang, Hongmei Chen, Jun Hua, Libing Zhou, and Haitao Lv. Novel mutations of polr3a gene caused hypomyelinating leukodystrophy type 7 (hld7) in a chinese family: a case report. ArXiv, Jun 2019. URL: https://doi.org/10.21203/rs.2.10640/v1, doi:10.21203/rs.2.10640/v1. This article has 0 citations.

9. (campopiano2020anovelpolr3a pages 1-2): Rosa Campopiano, Rosangela Ferese, Stefania Zampatti, Emiliano Giardina, Francesca Biagioni, Claudio Colonnese, Diego Centonze, Marianna Storto, Fabio Buttari, Edoardo Fraviga, Vania Broccoli, Mirco Fanelli, Francesco Fornai, and Stefano Gambardella. A novel polr3a genotype leads to leukodystrophy type-7 in two siblings with unusually late age of onset. BMC Neurology, Jun 2020. URL: https://doi.org/10.1186/s12883-020-01835-9, doi:10.1186/s12883-020-01835-9. This article has 13 citations and is from a peer-reviewed journal.

10. (ruan2024clinicalphenotypeand pages 12-13): Dan-dan Ruan, Xing-Lin Ruan, Ruolong Wang, Xin-fu Lin, Yan-ping Zhang, Bin Lin, Shi-jie Li, Min Wu, Qian Chen, Jian-Hui Zhang, Qiong Cheng, Yi-wu Zhang, Fan Lin, Jie-wei Luo, Zheng Zheng, and Yun-fei Li. Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by polr3a mutation. Scientific Reports, Apr 2024. URL: https://doi.org/10.1038/s41598-024-58452-6, doi:10.1038/s41598-024-58452-6. This article has 5 citations and is from a peer-reviewed journal.

11. (wu2019novelmutationsof pages 4-6): Shuiyan Wu, Zhenjiang Bai, Xingqiang Dong, Daoping Yang, Hongmei Chen, Jun Hua, Libing Zhou, and Haitao Lv. Novel mutations of polr3a gene caused hypomyelinating leukodystrophy type 7 (hld7) in a chinese family: a case report. ArXiv, Jun 2019. URL: https://doi.org/10.21203/rs.2.10640/v1, doi:10.21203/rs.2.10640/v1. This article has 0 citations.

12. (musumeci2022identificationofa pages 3-5): Antonino Musumeci, Francesco Calì, Carmela Scuderi, Mirella Vinci, Girolamo Aurelio Vitello, Sebastiano Antonino Musumeci, Valeria Chiavetta, Concetta Federico, Greta Amore, Salvatore Saccone, Gabriella Di Rosa, and Antonio Gennaro Nicotera. Identification of a novel missense mutation of polr3a gene in a cohort of sicilian patients with leukodystrophy. Biomedicines, 10:2276, Sep 2022. URL: https://doi.org/10.3390/biomedicines10092276, doi:10.3390/biomedicines10092276. This article has 16 citations.

13. (coulombe2024towardsatreatment pages 8-9): Benoit Coulombe, Alexandra Chapleau, Julia Macintosh, Thomas M. Durcan, Christian Poitras, Yena A. Moursli, Denis Faubert, Maxime Pinard, and Geneviève Bernard. Towards a treatment for leukodystrophy using cell-based interception and precision medicine. Biomolecules, 14:857, Jul 2024. URL: https://doi.org/10.3390/biom14070857, doi:10.3390/biom14070857. This article has 1 citations.

14. (coulombe2024towardsatreatment pages 2-4): Benoit Coulombe, Alexandra Chapleau, Julia Macintosh, Thomas M. Durcan, Christian Poitras, Yena A. Moursli, Denis Faubert, Maxime Pinard, and Geneviève Bernard. Towards a treatment for leukodystrophy using cell-based interception and precision medicine. Biomolecules, 14:857, Jul 2024. URL: https://doi.org/10.3390/biom14070857, doi:10.3390/biom14070857. This article has 1 citations.

15. (coulombe2024towardsatreatment pages 4-5): Benoit Coulombe, Alexandra Chapleau, Julia Macintosh, Thomas M. Durcan, Christian Poitras, Yena A. Moursli, Denis Faubert, Maxime Pinard, and Geneviève Bernard. Towards a treatment for leukodystrophy using cell-based interception and precision medicine. Biomolecules, 14:857, Jul 2024. URL: https://doi.org/10.3390/biom14070857, doi:10.3390/biom14070857. This article has 1 citations.

16. (ruan2024clinicalphenotypeand pages 13-13): Dan-dan Ruan, Xing-Lin Ruan, Ruolong Wang, Xin-fu Lin, Yan-ping Zhang, Bin Lin, Shi-jie Li, Min Wu, Qian Chen, Jian-Hui Zhang, Qiong Cheng, Yi-wu Zhang, Fan Lin, Jie-wei Luo, Zheng Zheng, and Yun-fei Li. Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by polr3a mutation. Scientific Reports, Apr 2024. URL: https://doi.org/10.1038/s41598-024-58452-6, doi:10.1038/s41598-024-58452-6. This article has 5 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00